Please assess the completion status of the following clinical trial:

Trial Title: LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Pathologically confirmed diagnosis of Stage IIIB / IV adenocarcinoma of the lung.~2. Documented activating epidermal growth factor receptor mutation (Del19 and/or L858R) with tumour tissues.~3. At least one measurable lesion according to response evaluation criteria in solid tumours version 1.1~4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.~5. Age \>= 18 years.~6. Adequate organ function as defined by the following criteria:~Serum aspartate transaminase(AST) and serum alanine transaminase(ALT) =\< 3 x upper limit of normal (ULN), or AST and ALT =\<5 x ULN if liver function abnormalities are due to underlying malignancy Total serum bilirubin =\<1.5 x ULN Absolute neutrophil count (ANC) \>=1.5 x 109/L Creatinine clearance \> 45ml / min Platelets \>= 75 x 109/L~Exclusion criteria:~1. Prior systemic chemotherapy for stage IIIB or IV non-small cell lung cancer. Neo-/adjuvant chemotherapy, chemoradiation or radiotherapy is permitted if at least 12 months has elapsed prior to disease progression.~2. Prior treatment with epidermal growth factor receptor targeting small molecules or antibodies.~3. Major surgery within 4 weeks of study randomisation.~4. Active brain metastases~5. Meningeal carcinomatosis.~6. Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured in the opinion of investigator.~7. Known pre-existing interstitial lung disease.~8. Clinically relevant cardiovascular abnormalities as judged by the investigator.~9. Cardiac left ventricular function with resting ejection fraction of less than institutional lower limit of normal.~10. Women of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 2 months after treatment has ended.~11. Pregnancy or breast-feeding.~12. Active hepatitis and/or known HIV carrier~13. Any prohibited concomitant medications for therapy with afatinib or gefitinib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- afatinib (Type: EXPERIMENTAL): afatinib once daily.
- gefitinib (Type: ACTIVE_COMPARATOR): gefitinib once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).